世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

Solid Formulations Drug Delivery- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Solid Formulations Drug Delivery- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031


The global market for Solid Formulations Drug Delivery was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast ... もっと見る

 

 

出版社 出版年月 電子版価格 納期 言語
QYResearch
QYリサーチ
2025年3月7日 US$3,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
5-7営業日 英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

Summary

The global market for Solid Formulations Drug Delivery was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Solid Formulations are a solid body drug delivery system of various weights and shapes, adapted for introduction into orifices of the human body.4 The external membrane of the suppository will typically melt, soften, or dissolve at body temperature which allows the active ingredient to then be absorbed by the surrounding tissue. Suppository bases usually employed are cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights, and fatty acid esters of polyethylene glycol. The suppository base employed has a marked influence on the release of the active ingredient incorporated in it.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Solid Formulations Drug Delivery, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Solid Formulations Drug Delivery by region & country, by Type, and by Application.
The Solid Formulations Drug Delivery market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Solid Formulations Drug Delivery.

Market Segmentation
By Company
Pfizer
Teva Pharmaceuticals
Bristol Myers Squibb
Lead Chemical
Purdue Pharma
Glenmark Pharmaceuticals
Galderma
Johnson & Johnson Private
GlaxoSmithKline
Bausch Health Companies
Hisamitsu Pharmaceuticals
Cipla
Bayer
Viatris
3M
Merck & Co
Crescita Therpeautics
Novartis International
Boehringer Ingelheim
Segment by Type
Powders
Suppositories
Segment by Application
Home Care Settings
Hospitals & Clinics
Burn Centers
Other Facilities
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Solid Formulations Drug Delivery company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Solid Formulations Drug Delivery in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Solid Formulations Drug Delivery in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.


ページTOPに戻る


Table of Contents

1 Market Overview
1.1 Solid Formulations Drug Delivery Product Introduction
1.2 Global Solid Formulations Drug Delivery Market Size Forecast (2020-2031)
1.3 Solid Formulations Drug Delivery Market Trends & Drivers
1.3.1 Solid Formulations Drug Delivery Industry Trends
1.3.2 Solid Formulations Drug Delivery Market Drivers & Opportunity
1.3.3 Solid Formulations Drug Delivery Market Challenges
1.3.4 Solid Formulations Drug Delivery Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Solid Formulations Drug Delivery Players Revenue Ranking (2024)
2.2 Global Solid Formulations Drug Delivery Revenue by Company (2020-2025)
2.3 Key Companies Solid Formulations Drug Delivery Manufacturing Base Distribution and Headquarters
2.4 Key Companies Solid Formulations Drug Delivery Product Offered
2.5 Key Companies Time to Begin Mass Production of Solid Formulations Drug Delivery
2.6 Solid Formulations Drug Delivery Market Competitive Analysis
2.6.1 Solid Formulations Drug Delivery Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Solid Formulations Drug Delivery Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Solid Formulations Drug Delivery as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Powders
3.1.2 Suppositories
3.2 Global Solid Formulations Drug Delivery Sales Value by Type
3.2.1 Global Solid Formulations Drug Delivery Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Solid Formulations Drug Delivery Sales Value, by Type (2020-2031)
3.2.3 Global Solid Formulations Drug Delivery Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Home Care Settings
4.1.2 Hospitals & Clinics
4.1.3 Burn Centers
4.1.4 Other Facilities
4.2 Global Solid Formulations Drug Delivery Sales Value by Application
4.2.1 Global Solid Formulations Drug Delivery Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Solid Formulations Drug Delivery Sales Value, by Application (2020-2031)
4.2.3 Global Solid Formulations Drug Delivery Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Solid Formulations Drug Delivery Sales Value by Region
5.1.1 Global Solid Formulations Drug Delivery Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Solid Formulations Drug Delivery Sales Value by Region (2020-2025)
5.1.3 Global Solid Formulations Drug Delivery Sales Value by Region (2026-2031)
5.1.4 Global Solid Formulations Drug Delivery Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Solid Formulations Drug Delivery Sales Value, 2020-2031
5.2.2 North America Solid Formulations Drug Delivery Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Solid Formulations Drug Delivery Sales Value, 2020-2031
5.3.2 Europe Solid Formulations Drug Delivery Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Solid Formulations Drug Delivery Sales Value, 2020-2031
5.4.2 Asia Pacific Solid Formulations Drug Delivery Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Solid Formulations Drug Delivery Sales Value, 2020-2031
5.5.2 South America Solid Formulations Drug Delivery Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Solid Formulations Drug Delivery Sales Value, 2020-2031
5.6.2 Middle East & Africa Solid Formulations Drug Delivery Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Solid Formulations Drug Delivery Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Solid Formulations Drug Delivery Sales Value, 2020-2031
6.3 United States
6.3.1 United States Solid Formulations Drug Delivery Sales Value, 2020-2031
6.3.2 United States Solid Formulations Drug Delivery Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Solid Formulations Drug Delivery Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Solid Formulations Drug Delivery Sales Value, 2020-2031
6.4.2 Europe Solid Formulations Drug Delivery Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Solid Formulations Drug Delivery Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Solid Formulations Drug Delivery Sales Value, 2020-2031
6.5.2 China Solid Formulations Drug Delivery Sales Value by Type (%), 2024 VS 2031
6.5.3 China Solid Formulations Drug Delivery Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Solid Formulations Drug Delivery Sales Value, 2020-2031
6.6.2 Japan Solid Formulations Drug Delivery Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Solid Formulations Drug Delivery Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Solid Formulations Drug Delivery Sales Value, 2020-2031
6.7.2 South Korea Solid Formulations Drug Delivery Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Solid Formulations Drug Delivery Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Solid Formulations Drug Delivery Sales Value, 2020-2031
6.8.2 Southeast Asia Solid Formulations Drug Delivery Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Solid Formulations Drug Delivery Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Solid Formulations Drug Delivery Sales Value, 2020-2031
6.9.2 India Solid Formulations Drug Delivery Sales Value by Type (%), 2024 VS 2031
6.9.3 India Solid Formulations Drug Delivery Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Profile
7.1.2 Pfizer Main Business
7.1.3 Pfizer Solid Formulations Drug Delivery Products, Services and Solutions
7.1.4 Pfizer Solid Formulations Drug Delivery Revenue (US$ Million) & (2020-2025)
7.1.5 Pfizer Recent Developments
7.2 Teva Pharmaceuticals
7.2.1 Teva Pharmaceuticals Profile
7.2.2 Teva Pharmaceuticals Main Business
7.2.3 Teva Pharmaceuticals Solid Formulations Drug Delivery Products, Services and Solutions
7.2.4 Teva Pharmaceuticals Solid Formulations Drug Delivery Revenue (US$ Million) & (2020-2025)
7.2.5 Teva Pharmaceuticals Recent Developments
7.3 Bristol Myers Squibb
7.3.1 Bristol Myers Squibb Profile
7.3.2 Bristol Myers Squibb Main Business
7.3.3 Bristol Myers Squibb Solid Formulations Drug Delivery Products, Services and Solutions
7.3.4 Bristol Myers Squibb Solid Formulations Drug Delivery Revenue (US$ Million) & (2020-2025)
7.3.5 Bristol Myers Squibb Recent Developments
7.4 Lead Chemical
7.4.1 Lead Chemical Profile
7.4.2 Lead Chemical Main Business
7.4.3 Lead Chemical Solid Formulations Drug Delivery Products, Services and Solutions
7.4.4 Lead Chemical Solid Formulations Drug Delivery Revenue (US$ Million) & (2020-2025)
7.4.5 Lead Chemical Recent Developments
7.5 Purdue Pharma
7.5.1 Purdue Pharma Profile
7.5.2 Purdue Pharma Main Business
7.5.3 Purdue Pharma Solid Formulations Drug Delivery Products, Services and Solutions
7.5.4 Purdue Pharma Solid Formulations Drug Delivery Revenue (US$ Million) & (2020-2025)
7.5.5 Purdue Pharma Recent Developments
7.6 Glenmark Pharmaceuticals
7.6.1 Glenmark Pharmaceuticals Profile
7.6.2 Glenmark Pharmaceuticals Main Business
7.6.3 Glenmark Pharmaceuticals Solid Formulations Drug Delivery Products, Services and Solutions
7.6.4 Glenmark Pharmaceuticals Solid Formulations Drug Delivery Revenue (US$ Million) & (2020-2025)
7.6.5 Glenmark Pharmaceuticals Recent Developments
7.7 Galderma
7.7.1 Galderma Profile
7.7.2 Galderma Main Business
7.7.3 Galderma Solid Formulations Drug Delivery Products, Services and Solutions
7.7.4 Galderma Solid Formulations Drug Delivery Revenue (US$ Million) & (2020-2025)
7.7.5 Galderma Recent Developments
7.8 Johnson & Johnson Private
7.8.1 Johnson & Johnson Private Profile
7.8.2 Johnson & Johnson Private Main Business
7.8.3 Johnson & Johnson Private Solid Formulations Drug Delivery Products, Services and Solutions
7.8.4 Johnson & Johnson Private Solid Formulations Drug Delivery Revenue (US$ Million) & (2020-2025)
7.8.5 Johnson & Johnson Private Recent Developments
7.9 GlaxoSmithKline
7.9.1 GlaxoSmithKline Profile
7.9.2 GlaxoSmithKline Main Business
7.9.3 GlaxoSmithKline Solid Formulations Drug Delivery Products, Services and Solutions
7.9.4 GlaxoSmithKline Solid Formulations Drug Delivery Revenue (US$ Million) & (2020-2025)
7.9.5 GlaxoSmithKline Recent Developments
7.10 Bausch Health Companies
7.10.1 Bausch Health Companies Profile
7.10.2 Bausch Health Companies Main Business
7.10.3 Bausch Health Companies Solid Formulations Drug Delivery Products, Services and Solutions
7.10.4 Bausch Health Companies Solid Formulations Drug Delivery Revenue (US$ Million) & (2020-2025)
7.10.5 Bausch Health Companies Recent Developments
7.11 Hisamitsu Pharmaceuticals
7.11.1 Hisamitsu Pharmaceuticals Profile
7.11.2 Hisamitsu Pharmaceuticals Main Business
7.11.3 Hisamitsu Pharmaceuticals Solid Formulations Drug Delivery Products, Services and Solutions
7.11.4 Hisamitsu Pharmaceuticals Solid Formulations Drug Delivery Revenue (US$ Million) & (2020-2025)
7.11.5 Hisamitsu Pharmaceuticals Recent Developments
7.12 Cipla
7.12.1 Cipla Profile
7.12.2 Cipla Main Business
7.12.3 Cipla Solid Formulations Drug Delivery Products, Services and Solutions
7.12.4 Cipla Solid Formulations Drug Delivery Revenue (US$ Million) & (2020-2025)
7.12.5 Cipla Recent Developments
7.13 Bayer
7.13.1 Bayer Profile
7.13.2 Bayer Main Business
7.13.3 Bayer Solid Formulations Drug Delivery Products, Services and Solutions
7.13.4 Bayer Solid Formulations Drug Delivery Revenue (US$ Million) & (2020-2025)
7.13.5 Bayer Recent Developments
7.14 Viatris
7.14.1 Viatris Profile
7.14.2 Viatris Main Business
7.14.3 Viatris Solid Formulations Drug Delivery Products, Services and Solutions
7.14.4 Viatris Solid Formulations Drug Delivery Revenue (US$ Million) & (2020-2025)
7.14.5 Viatris Recent Developments
7.15 3M
7.15.1 3M Profile
7.15.2 3M Main Business
7.15.3 3M Solid Formulations Drug Delivery Products, Services and Solutions
7.15.4 3M Solid Formulations Drug Delivery Revenue (US$ Million) & (2020-2025)
7.15.5 3M Recent Developments
7.16 Merck & Co
7.16.1 Merck & Co Profile
7.16.2 Merck & Co Main Business
7.16.3 Merck & Co Solid Formulations Drug Delivery Products, Services and Solutions
7.16.4 Merck & Co Solid Formulations Drug Delivery Revenue (US$ Million) & (2020-2025)
7.16.5 Merck & Co Recent Developments
7.17 Crescita Therpeautics
7.17.1 Crescita Therpeautics Profile
7.17.2 Crescita Therpeautics Main Business
7.17.3 Crescita Therpeautics Solid Formulations Drug Delivery Products, Services and Solutions
7.17.4 Crescita Therpeautics Solid Formulations Drug Delivery Revenue (US$ Million) & (2020-2025)
7.17.5 Crescita Therpeautics Recent Developments
7.18 Novartis International
7.18.1 Novartis International Profile
7.18.2 Novartis International Main Business
7.18.3 Novartis International Solid Formulations Drug Delivery Products, Services and Solutions
7.18.4 Novartis International Solid Formulations Drug Delivery Revenue (US$ Million) & (2020-2025)
7.18.5 Novartis International Recent Developments
7.19 Boehringer Ingelheim
7.19.1 Boehringer Ingelheim Profile
7.19.2 Boehringer Ingelheim Main Business
7.19.3 Boehringer Ingelheim Solid Formulations Drug Delivery Products, Services and Solutions
7.19.4 Boehringer Ingelheim Solid Formulations Drug Delivery Revenue (US$ Million) & (2020-2025)
7.19.5 Boehringer Ingelheim Recent Developments
8 Industry Chain Analysis
8.1 Solid Formulations Drug Delivery Industrial Chain
8.2 Solid Formulations Drug Delivery Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Solid Formulations Drug Delivery Sales Model
8.5.2 Sales Channel
8.5.3 Solid Formulations Drug Delivery Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医療)の最新刊レポート

本レポートと同じKEY WORD(drug)の最新刊レポート


よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2025/03/17 10:26

149.84 円

163.39 円

196.48 円

ページTOPに戻る